Plasma Biomarkers of Alzheimer Neuropathy Linked to Dementia Risk
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 1, 2024 -- Plasma biomarkers of Alzheimer disease (AD) neuropathy increase with age and are associated with known dementia risk factors, according to a study published online July 28 in the Journal of the American Medical Association to coincide with the Alzheimer's Association International Conference, held from July 28 to Aug. 1 in Philadelphia.
Yifei Lu, Ph.D., from the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill, and colleagues examined temporal plasma biomarker changes and their association with all-cause dementia among 1,525 participants from the U.S.-based Atherosclerosis Risk in Communities study. Plasma biomarkers were measured using stored specimens collected in midlife (mean age, 58.3 years) and late life (mean age, 76.0 years); participants were followed until a mean age of 80.7 years. The associations of biomarkers with incident all-cause dementia were assessed in a subgroup of 1,339 individuals.
Of the 1,525 participants, 16.5 percent developed dementia. The researchers found that from midlife to late life, there was a decreasing ratio of amyloid-β 42 to amyloid-β 40 (Aβ42:Aβ40) and increasing phosphorylated tau at threonine 181 (p-tau181), neurofilament light (NfL), and glial fibrillary acidic protein; more rapid changes in biomarkers were seen for participants harboring the apolipoprotein E epsilon 4 allele. Long-term associations were seen for AD-specific biomarkers in midlife with late-life dementia (hazard ratio per standard deviation [SD] lower Aβ42:Aβ40 ratio, 1.11; per SD higher p-tau181, 1.15). Significant associations were seen for all plasma biomarkers in late life with late-life dementia, with the largest association for NfL (hazard ratio per 1-SD increase, 1.92).
"The association of AD-specific biomarkers with dementia starts in midlife, whereas late-life measures of AD, neuronal injury, and astrogliosis biomarkers are all associated with dementia," the authors write.
Two authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Greater Neighborhood Disadvantage Tied to Inflammatory, Alzheimer Disease Biomarkers
THURSDAY, July 3, 2025 -- Greater neighborhood disadvantage is associated with increased inflammatory and Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in older...
Lower Risk of Alzheimer Disease Seen for Breast Cancer Survivors
MONDAY, June 30, 2025 -- Breast cancer survivors have a lower risk of Alzheimer disease (AD) compared with cancer-free controls, according to a study published online June 20 in...
Late-Life Mood Disorders May Indicate Predisposition to Dementia
MONDAY, June 30, 2025 -- Alzheimer disease (AD) and diverse non-AD tau pathologies may contribute to late-life mood disorders (LLMDs), according to a study published online June 9...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.